IDEXX LABORATORIES INC /DE Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, Tax
IDEXX LABORATORIES INC /DE (IDXX) reported Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, Tax of $146.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax · last filed 2026-02-20
- IDEXX LABORATORIES INC /DE other comprehensive (income) loss, defined benefit plan, before reclassification adjustment, tax for the quarter ending 2023-12-31 was -$267.00K, a 170.63% decline year-over-year.
- IDEXX LABORATORIES INC /DE other comprehensive (income) loss, defined benefit plan, before reclassification adjustment, tax for the quarter ending 2023-09-30 was $0.00.
- IDEXX LABORATORIES INC /DE other comprehensive (income) loss, defined benefit plan, before reclassification adjustment, tax for the quarter ending 2023-06-30 was $0.00.
- IDEXX LABORATORIES INC /DE other comprehensive (income) loss, defined benefit plan, before reclassification adjustment, tax for the quarter ending 2022-12-31 was $378.00K.
- IDEXX LABORATORIES INC /DE other comprehensive (income) loss, defined benefit plan, before reclassification adjustment, tax for fiscal 2025 was $146.00K.
- IDEXX LABORATORIES INC /DE other comprehensive (income) loss, defined benefit plan, before reclassification adjustment, tax for fiscal 2024 was -$130.00K.
- IDEXX LABORATORIES INC /DE other comprehensive (income) loss, defined benefit plan, before reclassification adjustment, tax for fiscal 2023 was -$267.00K.
- IDEXX LABORATORIES INC /DE other comprehensive (income) loss, defined benefit plan, before reclassification adjustment, tax for fiscal 2022 was -$613.00K.
| Period end | Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, Tax 3 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, Tax 6 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, Tax 9 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, Tax 12 month |
|---|---|---|---|---|
| 2025-12-31 | $146.00K 10-K · filed 2026-02-20 | |||
| 2024-12-31 | -$130.00K 10-K · filed 2026-02-20 | |||
| 2023-12-31 | -$267.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | -$267.00K derived: sum of 2 quarters · filed 2026-02-20 | -$267.00K derived: sum of 3 quarters · filed 2026-02-20 | -$267.00K 10-K · filed 2026-02-20 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-01 | $0.00 derived: sum of 2 quarters · filed 2023-11-01 | $0.00 10-Q · filed 2023-11-01 | |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-01 | $0.00 10-Q · filed 2023-08-01 | ||
| 2022-12-31 | $378.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $378.00K derived: sum of 2 quarters · filed 2025-02-21 | -$613.00K derived: sum of 3 quarters · filed 2025-02-21 | -$613.00K 10-K · filed 2025-02-21 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-01 | -$991.00K derived: sum of 2 quarters · filed 2023-11-01 | -$991.00K 10-Q · filed 2023-11-01 | |
| 2022-06-30 | -$991.00K 10-Q · filed 2023-08-01 | -$991.00K 10-Q · filed 2023-08-01 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $0.00 derived: sum of 2 quarters · filed 2024-02-22 | $0.00 derived: sum of 3 quarters · filed 2024-02-22 | $0.00 10-K · filed 2024-02-22 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-01 | $0.00 derived: sum of 2 quarters · filed 2022-11-01 | $0.00 10-Q · filed 2022-11-01 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-02 | $0.00 10-Q · filed 2022-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |